Difference between revisions of "Trastuzumab emtansine (Kadcyla)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
(clinical trials)
Line 8: Line 8:
  
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.
 +
 +
==Clinical trials==
 +
*[http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84883 EMILIA: A phase III, randomized, multicenter study of trastuzumab-DM1 (T-DM1) compared with lapatinib (L) plus capecitabine (X) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) and previously treated with a trastuzumab-based regimen.]<ref>S. Verma, V. Dieras, L. Gianni, D. Miles, M. Welslau, M. D. Pegram, J. Baselga, E. Guardino, L. Fang, C. M. Linehan, K. L. Blackwell. [http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84883 EMILIA: A phase III, randomized, multicenter study of trastuzumab-DM1 (T-DM1) compared with lapatinib (L) plus capecitabine (X) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) and previously treated with a trastuzumab-based regimen.] 2011 ASCO Annual Meeting abstract TPS116.</ref><ref>[http://clinicaltrials.gov/ct2/show/NCT00829166 EMILIA at ClinicalTrials.gov]</ref>
 +
*[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84827 MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC).]<ref>P. A. Ellis, C. H. Barrios, Y. Im, M. Patre, F. Branle, E. A. Perez. [http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84827 MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC).] 2011 ASCO Annual Meeting abstract TPS102.</ref><ref>[http://clinicaltrials.gov/ct2/show/NCT01120184 MARIANNE at ClinicialTrials.gov]</ref>
  
 
==Patient drug information==
 
==Patient drug information==

Revision as of 15:39, 12 July 2012

Also known as TDM1.

General information

Class: Antibody (Trastuzumab (Herceptin)) with linker to chemotherapeutic agent (emtansine). Humanized monoclonal antibody binds to subdomain IV of HER2, facilitating targeted delivery of a maytansine derivative that binds to tubulin at the rhizoxin binding site and inhibits the assembly of microtubules.[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Clinical trials

Patient drug information

No information available.

References

  1. ↑ ImmunoGen product site
  2. ↑ http://www.immunogen.com/img/T-DM1%20+%20pertuzumab%20at%20SABCS.pdf A Phase Ib/II Trial of Trastuzumab-DM1 (T-DM1) with Pertuzumab for Patients with HER2-Positive, Locally Advanced or Metastatic Breast Cancer: Interim Efficacy and Safety Results
  3. ↑ Dr. Sara Hurvitz's 2011 European Society for Medical Oncology (ESMO) Presentation
  4. ↑ S. Verma, V. Dieras, L. Gianni, D. Miles, M. Welslau, M. D. Pegram, J. Baselga, E. Guardino, L. Fang, C. M. Linehan, K. L. Blackwell. EMILIA: A phase III, randomized, multicenter study of trastuzumab-DM1 (T-DM1) compared with lapatinib (L) plus capecitabine (X) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) and previously treated with a trastuzumab-based regimen. 2011 ASCO Annual Meeting abstract TPS116.
  5. ↑ EMILIA at ClinicalTrials.gov
  6. ↑ P. A. Ellis, C. H. Barrios, Y. Im, M. Patre, F. Branle, E. A. Perez. MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC). 2011 ASCO Annual Meeting abstract TPS102.
  7. ↑ MARIANNE at ClinicialTrials.gov
Retrieved from "https://hemonc.org/w/index.php?title=Trastuzumab_emtansine_(Kadcyla)&oldid=1689"